The results showed that endothelial dysfunction and increased OS were present in subjects with IGT and IFG, indicating endothelial damage in these stages.

No abstract

the 2017 ELN revision (i.e. biallelic CEBPA, RUNX1, ASXL1, TP53 and FLT3-ITD allelic ratio) refined its prognostic impact. In our cohort, we found that indeed all markers had a significant impact on outcome except ASXL1 (DFS: P = .31; OS: P = .26). Summary/Conclusion:The 2010 ELN reporting system for AML is one of the most commonly used classifications and its prognostic impact is well established. Our validation study of the revised 2017 ELN risk classification, performed on a large cohort of younger adult de novo AML pts receiving intensive chemotherapy, showed that the Fav group has a significantly better outcome followed by the Int and Adv risk groups.